# Taisho Pharmaceutical Co., Ltd. clinical trials: 43 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 43 trials with Taisho Pharmaceutical Co., Ltd. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Taisho Pharmaceutical Co., Ltd.: 43 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/taisho-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 23, 2026 | NCT07548853 | A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis | Taisho Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Hyperphosphatemia Patients on Peritoneal Dialysis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548853) |
| April 23, 2026 | NCT07548840 | A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Taisho Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Hyperphosphatemia Patients on Hemodialysis | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548840) |
| December 16, 2025 | NCT07285304 | A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Taisho Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Hyperphosphatemia Patients on Hemodialysis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285304) |
| December 16, 2025 | NCT07285291 | A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | Taisho Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Hyperphosphatemia Patients on Hemodialysis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285291) |
| November 17, 2025 | NCT07231029 | A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Patients With Mild or Moderate Hepatic Impairment | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07231029) |
| July 25, 2025 | NCT07084961 | A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Adult Male Subjects | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07084961) |
| February 27, 2025 | NCT06849778 | An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Patients on Hemodialysis | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06849778) |
| February 20, 2025 | NCT06837155 | A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06837155) |
| February 20, 2025 | NCT06837142 | A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Male Subjects | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06837142) |
| December 20, 2024 | NCT06745531 | A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Taisho Pharmaceutical Co., Ltd. | Phase 3 | Completed | Hyperphosphatemia Patients on Hemodialysis | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06745531) |
| December 20, 2024 | NCT06745518 | A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | Taisho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Hyperphosphatemia Patients on Hemodialysis | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06745518) |
| September 19, 2024 | NCT06596356 | A Mass Balance Study of TS-172 in Healthy Adult Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Male Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06596356) |
| April 19, 2023 | NCT05819710 | A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Subjects | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05819710) |
| February 1, 2023 | NCT05707897 | A Food Effect Study of TS-142 in Healthy Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Effect of Food | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05707897) |
| January 26, 2023 | NCT05699239 | A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Taisho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Hyperphosphatemia Patients on Hemodialysis | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05699239) |
| November 22, 2022 | NCT05624944 | A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Patients with Mild or Moderate Hepatic Impairment | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05624944) |
| July 18, 2022 | NCT05461352 | Long-Term Study of TS-142 in Patients with Insomnia | Taisho Pharmaceutical Co., Ltd. | Phase 3 | Completed | Patients with Insomnia | 401 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05461352) |
| July 12, 2022 | NCT05453136 | Phase III Study of TS-142 in Patients with Insomnia | Taisho Pharmaceutical Co., Ltd. | Phase 3 | Completed | Patients with Insomnia | 1,155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05453136) |
| July 28, 2021 | NCT04979572 | A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses) | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Adult Subjects | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04979572) |
| May 5, 2021 | NCT04873323 | A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Subjects | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04873323) |
| March 24, 2021 | NCT04814771 | Mass Balance Study of TS-142 in Healthy Adult Subjects. | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Male Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04814771) |
| February 9, 2021 | NCT04746105 | A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea. | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Patients with Mild Obstructive Sleep Apnea Hypopnea | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04746105) |
| January 6, 2021 | NCT04696952 | A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Subjects | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04696952) |
| November 17, 2020 | NCT04631276 | Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects | Taisho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Subjects | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04631276) |
| October 5, 2020 | NCT04573725 | Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder | Taisho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Insomnia Disorder | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04573725) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 24 |
| Phase 2 | 6 |
| Phase 3 | 9 |
| Not applicable | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 39 |
| Recruiting | 3 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Sleep Initiation and Maintenance Disorders | 1 |
| Schizophrenia | 1 |
| Arthritis, Rheumatoid | 1 |
| Renal Insufficiency, Chronic | 1 |
| Narcolepsy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
- [Pediatric nephrology practices in the United States](https://specstream.ai/data/businesses/pediatric-nephrology-practices/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
- [Pest control companies in the United States](https://specstream.ai/data/businesses/pest-control-companies/united-states)
